Research area · week to 3 Oct 2026

Liver Disease Diagnosis and Treatment

Moving in Gut.

Moved this week: 1

Rebuilt 3 October 2026 at 3:19 pm AEST

Moved this week

Everything that moved →

Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality.
Gut · 29 July 2026 · Journal Article
Read the brief in JClub
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42527119
Open in JClub

Latest in Liver Disease Diagnosis and Treatment

Newest first · last 60 days

Surveillance of patients at risk of liver cancer: Expert opinions.
Journal of hepatology · 1 Oct 2026 · Review
Liver cancer surveillance faces limited support due to lack of randomized trial evidence, with false positives and low sensitivity impacting effectiveness.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42436054
Open in JClub
Liver stiffness dynamics in European populations - Authors' reply.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685729
Open in JClub
The changing epidemiology of primary liver cancer in the 21(st) century.
Journal of hepatology · 1 Oct 2026 · Review
Primary liver cancer cases and deaths increased by over 55% globally from 2000 to 2023, reversing previous declines and highlighting urgent public health needs.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42542384
Open in JClub
Liver stiffness dynamics in European populations.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685728
Open in JClub
Closing the policy gap: including children in the global agenda for steatotic liver disease.
Nature reviews. Gastroenterology & hepatology · 1 Oct 2026 · Letter
Read the brief in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42649274
Open in JClub
Noninvasive testing for fibrosis and cirrhosis in MASLD.
Nature reviews. Gastroenterology & hepatology · 1 Oct 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42613423
Open in JClub
The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Randomized Controlled Trial
DD01 significantly reduces liver fat by at least 30% in 76% of adults with MASH or MASLD after 12 weeks, outperforming placebo in a phase 2 trial.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42480572
Open in JClub
Building the Human Liver in a Dish: Organoids, Assembloids, and the Road to Precision Hepatology.
Gastroenterology · 1 Oct 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41932454
Open in JClub
A Neutrophil Defensin-VDAC1 Axis Drives Steatotic Liver Disease
bioRxiv · 28 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.19.752841
Open in JClub
CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease.
Gut · 24 Sept 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42386391
Open in JClub
Disrupted glucocorticoid rhythms selectively induce severe skeletal muscle insulin resistance and uncouple obesity from hepatic steatosis.
Cell Reports · 22 Sept 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42715103
Open in JClub
VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease.
EMBO Reports · 22 Sept 2026 · Journal Article
VGLL4 promotes MAFLD progression by enhancing PDK4 transcription, with overexpression causing steatosis and knockout offering protection in mice.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42773190
Open in JClub
Glutamine metabolism as a rheostat of CD4(+) T cell pathogenic function in metabolic dysfunction-associated steatotic liver disease.
Cell Metabolism · 18 Sept 2026 · Journal Article
Hepatic glutamine metabolism critically regulates pathogenic CD4(+) T cell inflammation, with Gln depletion linked to increased liver damage in MASLD.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42759512
Open in JClub
A Litmus Test for Confounding in Polygenic Scores
bioRxiv · 10 Sept 2026 · Preprint
Read the brief in JClub
- Open access
- 11 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.02.01.635985
Open in JClub
Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.
Nature reviews. Gastroenterology & hepatology · 9 Sept 2026 · Review
Multidisciplinary heart-liver co-management improves detection and treatment of MASLD, addressing a critical gap in cardiometabolic care with potential to reduce mortality.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42717057
Open in JClub
Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study.
Gut · 7 Sept 2026 · Journal Article
Pre-pregnancy parental obesity significantly increases the risk of adult offspring MASLD, with a 3.73-fold higher odds when both parents are overweight or obese.
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41735052
Open in JClub
Partial cure of chronic hepatitis B: potential implications for HCC surveillance?
Gut · 7 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/40730457
Open in JClub
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.
Gut · 7 Sept 2026 · Consensus Statement
Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases colorectal cancer (CRC) risk, especially with greater disease severity and metabolic burden, according to expert consensus.
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41770836
Open in JClub
Response to: Beyond gastrointestinal symptom burden: exploring the impact of previous cholecystectomy on ultrasound-based hepatocellular carcinoma surveillance in patients with liver cirrhosis.
Gut · 4 Sept 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42697714
Open in JClub
Cardiolipin deficiency disrupts electron transport chain and drives steatohepatitis.
eLife · 2 Sept 2026 · Journal Article
Cardiolipin deficiency in mitochondria impairs electron transport chain function and causes steatohepatitis in mice and humans.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42684124
Open in JClub
Emerging strategies for hepatocellular carcinoma surveillance: Abbreviated MRI, biomarkers and benefit stratification.
Journal of hepatology · 2 Sept 2026 · Review
Abbreviated MRI protocols and blood-based biomarkers show promise for improving hepatocellular carcinoma surveillance accuracy and patient adherence.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685984
Open in JClub
Steatotic liver disease in Latin America: current views and perspectives.
Nature reviews. Gastroenterology & hepatology · 1 Sept 2026 · Review
Latin America faces a high and rising burden of steatotic liver disease driven by obesity, alcohol use, and genetic factors, with significant health system challenges.
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42298140
Open in JClub
A decade of progress in cholestatic liver diseases: navigating a new era.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42556363
Open in JClub
Combination therapy in metabolic dysfunction-associated steatohepatitis.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42556356
Open in JClub
Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.
Journal of hepatology · 1 Sept 2026 · Journal Article
Spleen stiffness measurement ≤40 kPa accurately rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis, enabling endoscopy sparing.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42679862
Open in JClub
Updates in clinical science: Alcohol-related hepatitis.
Journal of hepatology · 1 Sept 2026 · Review
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42270545
Open in JClub
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid.
Journal of hepatology · 1 Sept 2026 · Journal Article
Read the brief in JClub
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42119851
Open in JClub
Erythrocyte Turnover: Unaddressed Confounder of PEth Prognosis in Alcohol-Related Liver Disease.
Gastroenterology · 1 Sept 2026 · Letter
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42217554
Open in JClub
Genomics-guided therapy in advanced primary liver cancers: A promising yet methodologically challenging landscape.
Journal of hepatology · 1 Sept 2026 · Letter
Read the brief in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42176808
Open in JClub
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Randomized Controlled Trial
Semaglutide 2·4 mg significantly improved liver fibrosis without worsening steatohepatitis in patients with fibrosis and cirrhosis, unlike the zalfermin combination.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42456707
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Liver Disease Diagnosis and Treatment

Browse JClub